DANBURY, Conn.--(BUSINESS WIRE)-- Biodel Inc. (Nasdaq: BIOD) will issue its second quarter fiscal year 2010 financial results on May 6, 2010. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
May 6, 2010 schedule:
4:00 pm EDT:
|Q2 fiscal year 2010 results will be|
|distributed by Business Wire|
4:15 pm EDT:
|Conference call participants should dial:|
|+1 (877) 303-8028 (United States) or|
|+1 (760) 536-5167 (International)|
4:30 pm EDT:
Conference call begins
Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at http://www.biodel.com. The audio webcast will be archived and available for replay through the website.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. Biodel's new drug application for its most advanced product candidate, VIAject(R), has been accepted for review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier stage product candidates include VIAtab(TM), a sublingual tablet formulation of insulin, a line of basal insulins and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at www.Biodel.com.
The Trout Group LLC
Seth D. Lewis, +1-617-583-1308
KEYWORDS: United States North America Connecticut
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical